March 21, 2016
Bloomberg BNA
On March 21, 2016, Sequenom Inc. asked the Supreme Court to review the Federal Circuit's decision to invalidate claims directed to methods for detecting paternally inherited cell-free fetal DNA in a mother’s blood—a decision that has had a major impact on the life sciences industry. The Federal Circuit's decision in Sequenom relied on the Supreme Court's ruling in Mayo, a ruling that many practitioners believe warrants clarification. Many practitioners also believe that the Federal Circuit's decision in Sequenom should lead companies to consider trade secret protection rather than relying on patents and/or to lobby Congress to clarify patent law. Bloomberg BNA contacted Finnegan attorney Howard W. Levine for his thoughts on Sequenom's petition.
Levine said, "If accepted, the cert. petition will provide the Supreme Court with the opportunity to reconsider its decision in Mayo and explain whether the federal courts have correctly interpreted the decision or have taken some of the language of the Mayo opinion that was applicable to a particularized set of facts out of context to create a rigid test that may not be relevant to all situations. Thus, the Supreme Court's decision in this case could have a profound effect on the ability to patent important life sciences inventions, particularly in the diagnostic field and in the burgeoning area of personalized medicine."
Sequenom Inc. v. Ariosa Diagnostics Inc., United States Court of Appeals for the Federal Circuit (CAFC), Supreme Court of the United States (SCOTUS)
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.